Financial releases

2019 annual results and business update

Exercise of warrants a great success

Crossject consolidates its financial structure via €5.7 million convertible bond issue

Structured financing of €2.6 million

Crossject signs a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Defense (DOD)

First-half 2019 results and business update

business up date : Focus on progress during last summer

Commercial agreement with DESITIN Pharma for ZENEO® Midazolam in Germany

End of the conversion of convertible bonds issued in 2018

Crossject - Slideshow Annual results 2018